Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population
Axmon, Anna LU
; El Mrayyan, Nadia
LU
; Eberhard, Jonas
LU
and Ahlström, Gerd
LU
(2019)
In BMC Psychiatry
19(1).
- Abstract
BACKGROUND: People with intellectual disability (ID) have high prevalence of psychiatric disorders, but even higher rates of prescription of psychotropic drugs. METHODS: Using Swedish national registers, we identified a group of older people with ID and diagnosis of mood disorders (ICD-10 codes F32-F39) and/or anxiety (ICD-10 code F4) during 2006-2012 (n = 587) and a referent group of people from the general population with the same diagnoses during the same time period (n = 434). For both groups, we collected information on prescription of anxiolytics, hypnotics and sedatives, antidepressants, and GABA-agonists. RESULTS: Among those with a diagnosis of anxiety, people with ID were more likely than those in the general population to be... (More)
BACKGROUND: People with intellectual disability (ID) have high prevalence of psychiatric disorders, but even higher rates of prescription of psychotropic drugs. METHODS: Using Swedish national registers, we identified a group of older people with ID and diagnosis of mood disorders (ICD-10 codes F32-F39) and/or anxiety (ICD-10 code F4) during 2006-2012 (n = 587) and a referent group of people from the general population with the same diagnoses during the same time period (n = 434). For both groups, we collected information on prescription of anxiolytics, hypnotics and sedatives, antidepressants, and GABA-agonists. RESULTS: Among those with a diagnosis of anxiety, people with ID were more likely than those in the general population to be prescribed anxiolytics (Relative Risk 1.32 [95% Confidence Interval 1.19-1.46]) and GABA-agonists (1.10 [1.08-1.31]). Moreover, among those with anxiety but without mood disorders, ID was associated with increased prescription of antidepressants (1.20 [1.03-1.39]). Within the ID cohort, behaviour impairment and MSP (i.e. moderate, severe, or profound) ID was associated with increased prescription of anxiolytics, both among those with anxiety (1.15 [1.03-1.30] for behaviour impairment and 1.23 [1.10-1.38] for MSP ID) and among those with mood disorders (1.14 [0.97-1.35] for behaviour impairment and 1.26 [1.04-1.52] for MSP ID). Moreover, MSP ID was associated with increased prescription of GABA-agonists among those with anxiety (1.23 [1.10-1.38]). CONCLUSIONS: The excess prescription of anxiolytics but not antidepressants may suggest shortages in the psychiatric health care of older people with intellectual disability and mood and anxiety disorders.
(Less)
- author
- Axmon, Anna
LU
; El Mrayyan, Nadia
LU
; Eberhard, Jonas
LU
and Ahlström, Gerd
LU
- organization
- publishing date
- 2019-08-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Aging, Down syndrome, Drug prescription, Mental retardation, Sedatives
- in
- BMC Psychiatry
- volume
- 19
- issue
- 1
- article number
- 238
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:31370823
- scopus:85071001081
- ISSN
- 1471-244X
- DOI
- 10.1186/s12888-019-2191-7
- project
- Ageing persons with intellectual disability, health and mortality, healthcare utilization and social welfare: a Swedish national longitudinal population study
- language
- English
- LU publication?
- yes
- id
- e03c8347-68e4-4869-ae1d-a592b9b1a6d7
- date added to LUP
- 2019-09-09 11:37:54
- date last changed
- 2024-07-10 01:39:40
@article{e03c8347-68e4-4869-ae1d-a592b9b1a6d7,
abstract = {{<p>BACKGROUND: People with intellectual disability (ID) have high prevalence of psychiatric disorders, but even higher rates of prescription of psychotropic drugs. METHODS: Using Swedish national registers, we identified a group of older people with ID and diagnosis of mood disorders (ICD-10 codes F32-F39) and/or anxiety (ICD-10 code F4) during 2006-2012 (n = 587) and a referent group of people from the general population with the same diagnoses during the same time period (n = 434). For both groups, we collected information on prescription of anxiolytics, hypnotics and sedatives, antidepressants, and GABA-agonists. RESULTS: Among those with a diagnosis of anxiety, people with ID were more likely than those in the general population to be prescribed anxiolytics (Relative Risk 1.32 [95% Confidence Interval 1.19-1.46]) and GABA-agonists (1.10 [1.08-1.31]). Moreover, among those with anxiety but without mood disorders, ID was associated with increased prescription of antidepressants (1.20 [1.03-1.39]). Within the ID cohort, behaviour impairment and MSP (i.e. moderate, severe, or profound) ID was associated with increased prescription of anxiolytics, both among those with anxiety (1.15 [1.03-1.30] for behaviour impairment and 1.23 [1.10-1.38] for MSP ID) and among those with mood disorders (1.14 [0.97-1.35] for behaviour impairment and 1.26 [1.04-1.52] for MSP ID). Moreover, MSP ID was associated with increased prescription of GABA-agonists among those with anxiety (1.23 [1.10-1.38]). CONCLUSIONS: The excess prescription of anxiolytics but not antidepressants may suggest shortages in the psychiatric health care of older people with intellectual disability and mood and anxiety disorders.</p>}},
author = {{Axmon, Anna and El Mrayyan, Nadia and Eberhard, Jonas and Ahlström, Gerd}},
issn = {{1471-244X}},
keywords = {{Aging; Down syndrome; Drug prescription; Mental retardation; Sedatives}},
language = {{eng}},
month = {{08}},
number = {{1}},
publisher = {{BioMed Central (BMC)}},
series = {{BMC Psychiatry}},
title = {{Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population}},
url = {{http://dx.doi.org/10.1186/s12888-019-2191-7}},
doi = {{10.1186/s12888-019-2191-7}},
volume = {{19}},
year = {{2019}},
}